by John A. Jenkins | Jun 13, 2024 | EPA, FOIA, Law Firms, Litigation, News Media
FOIAengine: ProPublica Reporter Made Dozens of FOIA Requests to EPA Before Dropping a Bombshell Minnesota-based 3M styles itself as a friendly, people-first company in the heartland of America, innovating through curiosity. Its 93,000 employees make all sorts of...
by John A. Jenkins | Jun 6, 2024 | FDA, FOIA, Law Firms, Litigation, Medical Devices
FOIAengine: Hundreds of FOIA Requests Signaled Challenge to FDA Two companies that go by the names of Triton Distribution and Vapetasia are small players in America’s fast-growing $28 billion e-cigarette market. Despite their size, they’ve become the unlikely...
by John A. Jenkins | May 16, 2024 | FDA, FOIA, Litigation, Non-Profits, Politics, SEC
FOIAengine: What Does the American Accountability Foundation Want to Know – and Why? This week we’re taking a look at the more than 100 Freedom of Information Act requests recently filed by the non-profit American Accountability Foundation. This group, a pugnacious...
by Randy E. Miller | Mar 27, 2024 | FDA, FOIA, Hedge Funds, Law Firms, Litigation, Non-Profits, Pharmaceuticals, Politics, Short-Selling, Stock Market
FOIAengine: Conservative Activists, Law Firms, Non-Profits Signal Competing Agendas A review of the most recent Freedom of Information Act requests made to the Food and Drug Administration illustrates how political organizations, law firms, news media, and financial...
by John A. Jenkins | Mar 6, 2024 | FOIA, Litigation, Short-Selling, Stock Market
FOIAengine Previews an April Fool’s Day Courtrooom Grudge Match This week’s story is about two litigation magnets. One is a household name whose lawsuit against OpenAI dominated the news a few days ago. That would be Elon Musk. The other – Aaron Greenspan –...
by Randy E. Miller | Feb 14, 2024 | FDA, FOIA, Hedge Funds, Litigation, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Breaks Down the Action Financial firms are continuing to monitor many of the pharmaceutical manufacturers we’ve reported on in recent months, including Krystal Biotech, Apellis Pharmaceuticals, Establishment Labs, Catalent and Astellas. That’s according to...
